01—Abstract
Summary
Summary of the 10-Q filed May 30, 2019. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. reported solid revenue growth for the six months ended April 30, 2019, with total net revenue increasing by 4% to $2,522 milliona compared to the prior year.
This growth was driven by strong performance in the Diagnostics and Genomics segment (+9%) and Agilent CrossLab (+8%), while the Life Sciences and Applied Markets segment remained flat. The company's net income for the six months was significantly impacted by a discrete tax benefit of $299 millionb related to Singapore tax incentives, resulting in a net income of $686 million, a substantial improvement from the net loss of $115 million in the prior year's comparable period which was affected by the U.S. Tax Cuts and Jobs Act. Operationally, Agilent maintained stable gross margins and operating margins, indicating effective cost management.
The company also demonstrated a commitment to returning capital to shareholders through $104 millionc in dividends paid and $125 million in share repurchases during the first six months of the fiscal year. Agilent's strong cash position and newly established $1 billion credit facility provide ample liquidity for ongoing operations and strategic initiatives.
02—Key points
Key Highlights
- Total net revenue increased by 4% year-over-year for the six months ended April 30, 2019, reaching $2.52 billion.
- The Diagnostics and Genomics segment showed strong growth with a 9% increase in revenue year-over-year for the first six months.
- Agilent CrossLab segment revenue grew by 8% year-over-year for the first six months, driven by services and supplies.
- Net income for the six months ended April 30, 2019 was $686 million, significantly boosted by a $299 million discrete tax benefit.
- Operating margin remained stable at 18.5% for the six months ended April 30, 2019, indicating consistent operational performance.
- The company returned $104 million to shareholders through dividends and $125 million through share repurchases in the first six months of fiscal 2019.
- Agilent entered into a new $1 billion, five-year unsecured credit facility in March 2019, enhancing its liquidity position.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2019, Agilent Technologies, Inc. kept $0.15.
- Revenue$1.24B100.0%
- Cost of revenue−$569.0M46.0%
- Gross profit$669.0M54.0%
- Operating costs−$453.0M36.6%
- Operating income$216.0M17.4%
- Interest, other & tax−$34.0M2.7%
- Net income$182.0M14.7%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2019filed May 30, 2019Financial Statements
Q2 FY2019 against Q2 FY2018
| Line item | Q2 FY2019Q2 FY2018 | Change |
|---|---|---|
| Revenue | $1.24B$1.21B | +2.7% |
| Cost of Revenue | $569.00M$563.00M | +1.1% |
| Gross Profit | $669.00M$643.00M | +4.0% |
| R&D Expenses | $99.00M$92.00M | +7.6% |
| SG&A Expenses | $354.00M$341.00M | +3.8% |
| Operating Expenses | $1.02B$996.00M | +2.6% |
| Operating Income | $216.00M$210.00M | +2.9% |
| Interest Expense | $17.00M$19.00M | −10.5% |
| Net Income | $182.00M$205.00M | −11.2% |
| EPS (Basic) | $0.57$0.64 | −10.9% |
| EPS (Diluted) | $0.57$0.63 | −9.5% |
| Shares Outstanding (Basic) | 317.00M322.00M | −1.6% |
| Shares Outstanding (Diluted) | 321.00M326.00M | −1.5% |
05—Questions
Frequently Asked Questions
What was the primary driver of the significant increase in net income for the six months ended April 30, 2019?
The substantial increase in net income for the six months ended April 30, 2019, primarily resulted from a discrete tax benefit of $299 million related to the restructuring and extension of the company's tax incentive in Singapore. This significantly offset other operational results and the prior year's tax-related charges.
How did Agilent's different business segments perform in terms of revenue?
For the six months ended April 30, 2019, Agilent Technologies saw varying performance across its segments. The Diagnostics and Genomics segment grew by 9% year-over-year, and Agilent CrossLab grew by 8%. The Life Sciences and Applied Markets segment was flat year-over-year. Overall total net revenue increased by 4%.
What is Agilent's approach to capital allocation and shareholder returns?
Agilent Technologies demonstrated a commitment to capital allocation by paying $104 million in dividends and repurchasing $125 million of its common stock during the first six months of fiscal 2019. The company has a new $1.75 billion share repurchase program authorized and continues to pay quarterly dividends, subject to board approval.
How is Agilent managing its liquidity and financial flexibility?
Agilent Technologies maintained a strong liquidity position with $2.155 billion in cash and cash equivalents as of April 30, 2019. Furthermore, the company secured a new $1 billion, five-year unsecured credit facility in March 2019, replacing its previous facility, providing significant financial flexibility for its operations and strategic initiatives.
06—Continue